One study evaluated the effect of real-time pop-up recommendations for lower-priced prescription alternatives, while a second study modeled capping monthly expenses and shifting the patients' savings back to the insurance plan.
20 Sep 2022
A sizable number of patients with diabetes do not consistently fill their prescriptions or take less than the prescribed amount due to costs, but there are ways to make it easier on a patient's pocketbook.
1 May 2022
Transparency in pricing, cost, and comparative value and elimination of restrictions on using quality-adjusted life-years in comparative effectiveness research are 2 of the recommendations.
29 Mar 2016
This issue includes stories on long-acting reversible contraceptives, medications for type 2 diabetes, and issues affecting the elderly.
1 May 2022
ACP has 4 concrete proposals to address rising prescription drug prices: regulating and negotiating prices, enhancing transparency, increasing competition, and considering value.
1 May 2016
The new policy paper is the third installment of a series. Previous papers have offered recommendations related to public health programs and pharmacy benefit managers.
15 Sep 2020
ACP called for increased transparency, lower out-of-pocket costs for patients, and improved access to affordable medications.
12 Nov 2019
ACP Spotlight offers readers a look at ACP's current top priorities and initiatives, as well as highlights from our e-newsletter, ACP Internist Weekly.
1 Jan 2020
ACP's members can meet the challenges of today's world by becoming more involved in their local chapters, serving on national committees, or running for leadership positions within the national organization.
1 Mar 2017
Treatment value was highest in patients with class II heart failure, who also benefited most from treatment in the PARADIGM-HF trial, and improved outcomes with the drug would need to be sustained for at least 36 months to keep the cost per quality-adjusted life-year below a $100,000 threshold.
30 Aug 2016